- Home
- PETS vs BCAB Comparison
PETS vs BCAB Comparison
Compare PETS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | BCAB |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PETS | BCAB |
|---|---|---|
| Price | $3.53 | $0.74 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $3.20 | $1.00 |
| AVG Volume (30 Days) | ★ 7.7M | 1.1M |
| Earning Date | 02-09-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $198,265,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $0.24 |
| 52 Week High | $5.58 | $1.43 |
Technical Indicators
Market Signals| Indicator | PETS | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 67.22 | 47.18 |
| Support Level | $3.36 | $0.63 |
| Resistance Level | $3.64 | $0.83 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 76.17 | 49.26 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.